Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
PACIFICA
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
- NCT03165734 ↗
- Active, not recruiting
- Swedish Orphan Biovitrum
- Deep
We haven't built an HCP commentary report on PACIFICA (pacritinib in myelofibrosis with severe thrombocytopenia) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on PACIFICA so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| Podcasts | 19 | |
| X threads | 15 | |
| YouTube | 14 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis With Severe Thrombocytopenia (Platelet Count <50,000/μL)(PACIFICA)
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
- Interventions
- Pacritinib; Physician's Choice medications
- Arms
- Pacritinib 200 mg BID · Experimental
- Physician's Choice (P/C) therapy · Active comparator
- Enrollment
- 407
- Primary outcomes
- Spleen volume
- Total Symptom Score (TSS) (excluding tiredness)
- Sponsor
- Swedish Orphan Biovitrum with PSI CRO
- Start
- Jun 26, 2017
- Primary completion
- Oct 5, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT03165734 · updated Apr 30, 2026
Publications
linked from the registry- Gerds AT, Savona MR, Scott BL, Talpaz M, Egyed M, Harrison CN, Yacoub A, Vannucchi A, Mead AJ, Kiladjian JJ, O'Sullivan J, Garcia-Gutierrez V, Bose P, Rampal RK, Miller CB, Palmer J, Oh ST, Buckley SA, Mould DR, Ito K, Tyavanagimatt S, Smith JA, Roman-Torres K, Devineni S, Craig AR, Mascarenhas JO. Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis. Blood Adv. 2020 Nov 24;4(22):5825-5835. doi: 10.1182/bloodadvances.2020003314. PubMed 33232476